We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Abnormalities of B Lymphocytes During Systemic Lupus

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00401141
First Posted: November 17, 2006
Last Update Posted: August 8, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University Hospital, Strasbourg, France
  Purpose
Previous experimental data strongly suggest that B lymphocytes have intrinsic abnormalities during lupus in mice spontaneously affected by the disease. This study tries to define these abnormalities by looking at the gene expression profile of purified B lymphocytes from patients with non active systemic lupus , compared with the gene expression profile of purified B lymphocytes from healthy donnors.

Condition Intervention
Systemic Lupus Erythematosus Procedure: Blood samples

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Phenotypic Characteristics and Transcriptomas of B Lymphocytes During Non Active Systemic Lupus Erythematosus

Resource links provided by NLM:


Further study details as provided by University Hospital, Strasbourg, France:

Estimated Enrollment: 30
Study Start Date: April 2004
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

  • non active systemic lupus

Exclusion criteria:

  • immunosuppressive drugs
  • more than 10 mg of prednisone per day
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00401141


Locations
France
Service d'Immunologie Clinique et VIH - Hôpital Civil
Strasbourg, France, 67091
Sponsors and Collaborators
University Hospital, Strasbourg, France
Investigators
Study Director: Jean-Louis Pasquali, MD Hôpitaux Universitaires de Strasbourg
  More Information

ClinicalTrials.gov Identifier: NCT00401141     History of Changes
Other Study ID Numbers: 3156
First Submitted: November 16, 2006
First Posted: November 17, 2006
Last Update Posted: August 8, 2008
Last Verified: August 2008

Keywords provided by University Hospital, Strasbourg, France:
Systemic lupus
B lymphocytes
transcriptomas

Additional relevant MeSH terms:
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases